Cinqair
(Reslizumab)PreclinicalMonoclonal antibody
TevaReslizumab is used to treat a specific type of severe asthma in adults and children where the body produces too many of a certain type of white blood cell called eosinophils, which cause airway inflammation and breathing problems.[1] Cinqair is currently being investigated across 1 indication[3], with its most advanced program in Preclinical.[1]
Cinqair is one of 29 small molecule programs targeting Airway obstruction. It is currently in Preclinical.
1
Indications
22
Total Trials
0
Active Trials
28
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
31 competitors in Airway Obstruction
#DrugCompanyPhaseTrials
1Brethine
SanofiApproved
Theo-Dur
PfizerApproved
Daliresp
AstraZenecaApproved
Onbrez
NovartisApproved
Adrenaline
SSamson Clinical Operations Pty Ltd
Approved
Kenalog
BBassett Healthcare
Approved
Foradil
ViatrisApproved
Alvesco
AAzurity Pharmaceuticals
Approved
Celestone
SSchering-Plough
Approved
Qvar
SSchering-Plough
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Asthma13 trials
Similarities and Differences of Biological Therapies for Severe Asthma.
Unknown status·—··NCT04665141·600 enrolled
Show 10 more trials
Chronic Rhinosinusitis2 trials
Effect of Reslizumab in Chronic Rhinosinusitis
Unknown status·—·Phase 3·NCT02799446·30 enrolled
Eosinophilic Esophagitis2 trials
Inflammation1 trial
3 more indications
Interleukin1 trial
Loiasis1 trial
Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT01111305·31 enrolled
Unspecified1 trial
Regulatory
FDA Approval Timeline[4]
Mar 23, 2016
CINQAIR
BLA BLA761033
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Reslizumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]